Cargando…
Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia
BACKGROUND AND PURPOSE: Abundant studies have shown that lncRNA PANDAR plays an oncogenic role in human solid tumors. Although abnormal expression of PANDAR has been well investigated in solid tumors, it was rarely studied in hematologic diseases. Hence, the aim of this study was to determine the PA...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214337/ https://www.ncbi.nlm.nih.gov/pubmed/30464600 http://dx.doi.org/10.2147/CMAR.S180150 |
_version_ | 1783367969658634240 |
---|---|
author | Yang, Lan Zhou, Jing-Dong Zhang, Ting-Juan Ma, Ji-Chun Xiao, Gao-Fei Chen, Qin Deng, Zhao-Qun Lin, Jiang Qian, Jun Yao, Dong-Ming |
author_facet | Yang, Lan Zhou, Jing-Dong Zhang, Ting-Juan Ma, Ji-Chun Xiao, Gao-Fei Chen, Qin Deng, Zhao-Qun Lin, Jiang Qian, Jun Yao, Dong-Ming |
author_sort | Yang, Lan |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Abundant studies have shown that lncRNA PANDAR plays an oncogenic role in human solid tumors. Although abnormal expression of PANDAR has been well investigated in solid tumors, it was rarely studied in hematologic diseases. Hence, the aim of this study was to determine the PANDAR expression level and its clinical significance in patients with acute myeloid leukemia (AML). MATERIALS AND METHODS: For detecting the expression level of PANDAR in 119 AML patients and 26 controls, real-time quantitative PCR was used in this study. The prognostic values were evaluated by using Kaplan–Meier analysis, Cox regression analyses, and logistic regression analysis. RESULTS: PANDAR was significantly overexpressed in AML and might be a promising biomarker which could distinguish AML from normal samples (P<0.001). Patients with high expression of PANDAR (PANDAR(high)) were older and showed higher bone marrow blasts than patients in PANDAR(low) group (P=0.029 and 0.032, respectively). Significant differences between these groups were also detected regarding risk group and karyotype finding (P=0.009 and 0.041, respectively). Importantly, PANDAR(high) patients presented a significant lower complete remission rate compared to PANDAR(low) patients (P<0.001). Furthermore, Kaplan–Meier analysis showed that PANDAR(high) patients had shorter overall survival compared to PANDAR(low) patients observing the whole AML cohort, and also in the non-M3 group of patients (P<0.001 and P=0.005, respectively). Multivariate analysis of Cox and logistic regression analysis confirmed that high PANDAR expression was an independent unfavorable risk factor for overall survival and complete remission in both observed patient groups. CONCLUSION: These results revealed that PANDAR was overexpressed in AML, and that higher PANDAR expression was associated with poor clinical outcome. Our study therefore suggests that PANDAR expression is a promising biomarker for prognostic prediction for AML. |
format | Online Article Text |
id | pubmed-6214337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62143372018-11-21 Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia Yang, Lan Zhou, Jing-Dong Zhang, Ting-Juan Ma, Ji-Chun Xiao, Gao-Fei Chen, Qin Deng, Zhao-Qun Lin, Jiang Qian, Jun Yao, Dong-Ming Cancer Manag Res Original Research BACKGROUND AND PURPOSE: Abundant studies have shown that lncRNA PANDAR plays an oncogenic role in human solid tumors. Although abnormal expression of PANDAR has been well investigated in solid tumors, it was rarely studied in hematologic diseases. Hence, the aim of this study was to determine the PANDAR expression level and its clinical significance in patients with acute myeloid leukemia (AML). MATERIALS AND METHODS: For detecting the expression level of PANDAR in 119 AML patients and 26 controls, real-time quantitative PCR was used in this study. The prognostic values were evaluated by using Kaplan–Meier analysis, Cox regression analyses, and logistic regression analysis. RESULTS: PANDAR was significantly overexpressed in AML and might be a promising biomarker which could distinguish AML from normal samples (P<0.001). Patients with high expression of PANDAR (PANDAR(high)) were older and showed higher bone marrow blasts than patients in PANDAR(low) group (P=0.029 and 0.032, respectively). Significant differences between these groups were also detected regarding risk group and karyotype finding (P=0.009 and 0.041, respectively). Importantly, PANDAR(high) patients presented a significant lower complete remission rate compared to PANDAR(low) patients (P<0.001). Furthermore, Kaplan–Meier analysis showed that PANDAR(high) patients had shorter overall survival compared to PANDAR(low) patients observing the whole AML cohort, and also in the non-M3 group of patients (P<0.001 and P=0.005, respectively). Multivariate analysis of Cox and logistic regression analysis confirmed that high PANDAR expression was an independent unfavorable risk factor for overall survival and complete remission in both observed patient groups. CONCLUSION: These results revealed that PANDAR was overexpressed in AML, and that higher PANDAR expression was associated with poor clinical outcome. Our study therefore suggests that PANDAR expression is a promising biomarker for prognostic prediction for AML. Dove Medical Press 2018-10-29 /pmc/articles/PMC6214337/ /pubmed/30464600 http://dx.doi.org/10.2147/CMAR.S180150 Text en © 2018 Yang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Yang, Lan Zhou, Jing-Dong Zhang, Ting-Juan Ma, Ji-Chun Xiao, Gao-Fei Chen, Qin Deng, Zhao-Qun Lin, Jiang Qian, Jun Yao, Dong-Ming Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia |
title | Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia |
title_full | Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia |
title_fullStr | Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia |
title_full_unstemmed | Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia |
title_short | Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia |
title_sort | overexpression of lncrna pandar predicts adverse prognosis in acute myeloid leukemia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214337/ https://www.ncbi.nlm.nih.gov/pubmed/30464600 http://dx.doi.org/10.2147/CMAR.S180150 |
work_keys_str_mv | AT yanglan overexpressionoflncrnapandarpredictsadverseprognosisinacutemyeloidleukemia AT zhoujingdong overexpressionoflncrnapandarpredictsadverseprognosisinacutemyeloidleukemia AT zhangtingjuan overexpressionoflncrnapandarpredictsadverseprognosisinacutemyeloidleukemia AT majichun overexpressionoflncrnapandarpredictsadverseprognosisinacutemyeloidleukemia AT xiaogaofei overexpressionoflncrnapandarpredictsadverseprognosisinacutemyeloidleukemia AT chenqin overexpressionoflncrnapandarpredictsadverseprognosisinacutemyeloidleukemia AT dengzhaoqun overexpressionoflncrnapandarpredictsadverseprognosisinacutemyeloidleukemia AT linjiang overexpressionoflncrnapandarpredictsadverseprognosisinacutemyeloidleukemia AT qianjun overexpressionoflncrnapandarpredictsadverseprognosisinacutemyeloidleukemia AT yaodongming overexpressionoflncrnapandarpredictsadverseprognosisinacutemyeloidleukemia |